iNovacia

Press release Stockholm 2011-06-28

iNovacia Further Develops its Compound Collection

iNovacia, the drug discovery service provider and subsidiary of Kancera AB (Nasdaq OMX

Stockholm First North, KAN), today announced the addition of over 20,000 novel compounds to its

small-molecule screening collection. This is in line with the continuous development to maintain a

world leading library offered to its international pharma and biotech clients.

The new and novel compounds have been developed in an exclusive joint effort together with

Asinex Ltd in Moscow. Before the addition the iNovacia screening collection consisted of

approximately 280,000 compounds selected based on diversity, novelty and lead-likenesses. “Our

screening collection is now reaching 300,000 compounds. The size and the chemical diversity of the

library is well adapted for vigorous screening to develop new drug candidates. The key is to combine

diversity and novelty with compounds of high purity and which are amenable for rapid optimization”

says Dr. Martin Norin, Chief Operating Officer at iNovacia. He continues: “Our chemists

continuously synthesize novel scaffolds to enrich our collection even further. Typically, we have

about 50-100 compounds per scaffold in our library and we have an excellent track-record in

delivering viable hit and lead series to our clients”.

Earlier this year, iNovacia introduced new filters identifying e.g. Pan Assay Interference

Compounds (PAINS), promiscuous compounds that may appear as frequent false positive hits in

screening campaigns, and the replacement of such compounds in the collection. This is also in line

with iNovacia’s strategy to maintain a screening collection of the very highest quality.

About iNovacia

iNovacia provides high-throughput screening, fragment-based screening and other drug discovery

services to translate targets into validated leads for pharmaceutical and biotech companies.

Enabled by a chemical library of highest international standard, unique biophysical tools for

characterization of mode-of-action and SAR, iNovacia can minimize the technical risk and optimize

lead-time and quality of drug discovery projects. iNovacia is a wholly owned subsidiary of Kancera

AB (Nasdaq OMX Stockholm First North, KAN).

About Kancera AB (publ)

Kancera develops the basis for new therapeutics, starting with new treatment concepts and ending

with drug candidate. Kancera is currently running two projects, one to develop a treatment

leukemia and one project targeting cancer’s ability to generate energy in order to survive. Kancera

also develops novel cancer models that provide clinically relevant information on drug candidates

before clinical trials are started. Kancera’s operations are run at Pharmacia’s former premises at

Kungsholmen in Stockholm, Sweden. Kancera employs 20 people. The share is traded at

NASDAQ OMX First North. The number of shareholders is approximately 1200. Remium AB is the

Certified Advisor to Kancera.

For further information, please contact:

Thomas Olin, CEO +46 735 20 40 01 or thomas.olin@inovacia.se

iNovacia AB Lindhagensgatan 133 SE 112 51 Stockholm www.inovacia.se